The Private-Equity Takeover of Eating-Disorder Treatment — and Why Public Investors Can't Access It

The Emily Program, a nationally recognised eating-disorder treatment provider, recently announced it would appear at the Minnesota State Fair alongside other mental-health organisations. The press release sounds like a community initiative. It is, in fact, a window onto one of the most quietly transformative consolidation waves in American healthcare.

The Emily Program, founded in 1993, is no longer an independent company. It is the flagship brand of Accanto Health, a private-equity-backed holding company created in 2021 when The Emily Program and another major provider, Veritas Collaborative, merged. By 2024, even the dual-brand structure was folded away: Veritas was rebranded as The Emily Program. The combined organisation operates more than 20 locations across seven states, offering everything from residential care to intensive outpatient therapy. It is not publicly traded. Its owners are private-equity firms — Vestar Capital Partners and TT Capital Partners — and its investors are the partners and limited partners of those firms.

The same playbook has been applied across the entire eating-disorder treatment sector. A small number of large, multi-site entities now own most of the country's residential and day-treatment centres. Discovery Behavioral Health, backed by Webster Equity Partners, operates over 150 centres in 16 states. Monte Nido, invested in by Levine Leichtman Capital Partners and later sold to Revelstoke for approximately $725 million, grew to 22 facilities through acquisitions and new openings. The Eating Recovery Center, acquired first by Lee Equity Partners and then resold in 2021 for $1.4 billion, illustrates how the model works: buy the provider, aggregate competitors, expand, and exit at a steep multiple.

The broader behavioural-health acquisition data tell the same story. The number of behavioural-health facilities involved in M&A deals rose from 32 in 2010 to 1,330 in 2021. Valuation multiples for mental-health outpatient providers now range from 10 to 14 times EBITDA at the platform level, with premiums for scaled, multi-state operations. The United States behavioural-health market was valued at approximately $97 billion in 2025 and is projected to exceed $159 billion by 2035. This is not a niche. It is a major growth segment of the healthcare system, and the value has been captured almost entirely by private capital.

For public-market investors, this creates an awkward situation. The most successful consolidation stories in behavioural health are inaccessible. The companies that do offer exposure through publicly traded shares operate under a very different set of economics, incentives, and risks.

Two publicly traded providers dominate the segment. Acadia Healthcare, listed on Nasdaq under the ticker ACHC, operates 279 behavioural-healthcare facilities with approximately 12,600 beds across 40 states. Universal Health Services, on the New York Stock Exchange as UHS, runs a much larger portfolio of acute-care and behavioural hospitals, with quarterly revenues exceeding $4.5 billion. The two companies are roughly in the same business — providing inpatient and outpatient behavioural-health treatment, largely to patients covered by commercial insurance and Medicaid — but their financial profiles are dramatically different.

Acadia Healthcare has struggled. It reported negative trailing twelve-month earnings per share of $12.42 as of mid-2026, with a market capitalisation around $2.85 billion — a fraction of where it traded before a series of facility closures, operational missteps, and a costly debt load eroded investor confidence. Its second-quarter 2026 revenue of $866 million was up year on year, but earnings of $0.38 per share barely exceeded the consensus estimate of $0.36, according to the market-data service. AInvest's aggregate signal rates ACHC a Buy, reflecting the possibility that the worst is behind it and that its bed base could expand profitably. The trouble is that expansion in a private-equity-saturated market means competing for patients, staff, and payer contracts against well-capitalised, privately held platforms that are not constrained by quarterly earnings calls.

Universal Health Services, by contrast, has grown steadily. Its second-quarter 2026 revenue reached $4.64 billion, and it earned $5.98 per diluted share, beating the consensus estimate of $5.94, according to the market-data service. With a market capitalisation near $15 billion, UHS is the larger and more diversified player, with acute-care hospital operations that cushion its behavioural-health segment against demand shocks. In March 2026, it announced the acquisition of Talkspace, a digital mental-health platform, signalling an ambition to own both the physical and virtual ends of the behavioural-health continuum. AInvest's aggregate signal rates UHS a Hold, suggesting that while the company is well run, its valuation already reflects much of the visible growth.

The structural dynamic between these public companies and the private-equity platforms is the point. Private equity in healthcare operates on a different clock and with different constraints. It buys, consolidates, leverages, and exits — often within a five-to-seven-year window. The strategy works when demand is rising, when payer reimbursement supports margins, and when the regulatory environment tolerates market concentration. All three conditions have held for eating-disorder and behavioural-health treatment, at least until recently.

The trouble is that the regulatory environment may not hold. In 2024, the Federal Trade Commission, the Department of Justice, and the Department of Health and Human Services launched a joint inquiry into private-equity firms' increasing control over healthcare companies and professionals. The FTC updated Hart-Scott-Rodino filing thresholds in 2025, broadening the scope of deals that must be reported before closing. States from Massachusetts to Oregon have enacted laws regulating or blocking private-equity medical acquisitions. The antitrust apparatus, which for years was relatively passive on healthcare services M&A, is becoming active.

This matters for the economics of the consolidation story. If roll-ups face higher regulatory costs, longer closing timelines, or blocked transactions, the multiples that justify private-equity investments decline. A platform that was worth 14 times EBITDA because it could keep acquiring adds-on may trade closer to 10 if those acquisitions stall. The exit options — sale to a strategic buyer or IPO — become harder when the buyer's own consolidation ambitions are under scrutiny.

For the publicly traded behavioural-health companies, the regulatory shift cuts both ways. On the one hand, if private-equity platforms cannot continue to expand, the competitive pressure on public companies eases. ACHC, with its large bed base and turnaround narrative, would benefit from a slower-moving, less capital-intensive competitive landscape. On the other hand, if the same regulatory scrutiny extends to publicly traded acquirers, UHS's integration of Talkspace and any future behavioural-health acquisitions could face headwinds. The FTC does not distinguish between public and private buyers when it comes to antitrust.

The demand-side picture provides a different lens. Eating disorders carry enormous economic costs. A 2022 study estimated that eating disorders cost the United States healthcare system $64.7 billion annually — approximately $11,800 per affected individual, with Medicare beneficiaries carrying more than $20,000 in related costs. Payers, including private insurers and government programs, have a financial interest in early, effective treatment that reduces downstream hospitalisation and chronic-care utilisation. Private-equity-owned providers, however, have drawn criticism for cherry-picking patients with well-funded private insurance and largely avoiding public assistance, which concentrates financial risk elsewhere and may drive up overall system costs.

This is the incentive structure that an investor should keep in mind. The companies winning the most money in behavioural health are the ones that have found the right intersection of rising demand, payer willingness, and regulatory tolerance. The publicly traded operators — whether they are turning around, growing steadily, or chasing new segments — must compete in a market where the best-capitalised players do not report to shareholders, do not publish quarterly earnings, and can make multi-year expansion bets without public scrutiny. The Emily Program at a state-fair booth is a small signal from that private world. The investment question is whether the public-market alternatives can catch up, or whether they are destined to be the less-capitalised competitors in a game increasingly played by others.